Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored and one such agent, lapatinib, is in clinical practice but with modest activity. Through chemical screening, we discovered a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hidekazu, Hirata, Michinari, Shinonome, Satomi, Wada, Toru, Iguchi, Motofumi, Dohi, Keiji, Inoue, Makiko, Ishioka, Yukichi, Hojo, Kanji, Yamada, Tomomi, Sugimoto, Tatsuya, Masuno, Koichi, Nezasa, Ken-ichi, Sato, Norihito, Matsuo, Kenji, Yonezawa, Shuji, Frenkel, Eugene P, Shichijo, Michitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317859/
https://www.ncbi.nlm.nih.gov/pubmed/24837299
http://dx.doi.org/10.1111/cas.12449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317859/
https://www.ncbi.nlm.nih.gov/pubmed/24837299
http://dx.doi.org/10.1111/cas.12449

Ejemplares similares